期刊文献+

浅表膀胱癌TURBt术后吡柔比星膀胱保留灌注化疗预防复发的随访研究 被引量:2

Follow-up study on recurrence prevention by pirarubicin bladder preservation perfusion chemotherapy after TURBt of superficial bladder cancer
下载PDF
导出
摘要 目的随访观察浅表膀胱癌经尿道膀胱肿瘤电切术(TURBt)后吡柔比星膀胱保留灌注化疗对干预膀胱癌复发的影响。方法选取浅表膀胱癌TURBt术后患者109例,分为观察组62例和对照组47例。术后,对照组未给予膀胱保留灌注化疗,观察组予以膀胱保留灌注吡柔比星治疗,随访2年,观察两组的复发率,以及观察组膀胱保留灌注化疗的不良反应。结果术后3~6个月内,对照组膀胱癌复发率呈下降趋势,此后呈逐渐升高的趋势;观察组各时间段内膀胱癌复发率基本呈现降低趋势;两组累积复发率均呈逐渐升高的趋势,但观察组累积复发率升高趋势平缓,而对照组累积复发率升高趋势急剧。各时间段内观察组膀胱癌复发率、累积复发率均低于对照组(P<0.05)。结论吡柔比星膀胱保留灌注化疗有效降低了浅表膀胱癌TURBt术后膀胱癌的复发率,且未出现严重的不良反应,临床应用比较安全,对预防TURBt术后膀胱癌复发具有积极而重要的干预意义。 Objective To follow up the influence on recurrence prevention by pirarubicin bladder preservation perfusion chemotherapy after transurethral resection of bladder tumor (TURBO of superficial bladder cancer. Methods 109 cases of superficial bladder cancer after TURBt were included and divided into observation group with 62 cases and control group with 47 cases. After operation, patients in control group were treated without pirarubicin bladder preservation perfusiou chemotherapy, yet patients in observation group were treated with pirarubicin bladder preservation perfusion chemotherapy. They were followed up for 2 years to observe their relapse rate, also adverse reaction of observation group. Results 3~6 months later after operation, control group's recurrence rate decreased, then increased, and observation group's recurrence rate decreased. Two group's cumulative recurrence rate increased, but observation group's cumulative recurrence rate increased flat gently, yet control group's cumulative recur- rence rate increased sharply. Observation group's recurrence rate and cumulative recurrence rate at different time point were all lower than that of control group (P〈0.01 or P〈0.05). Observation group's adverse reaction incidence was 9.68%, including chemical cystitis, fatigue, fever, tachycardia, yet without other serious adverse reactions. Conclusion It effectively reduces recurrence rate of superficial bladder cancer after TURBt by piraru- bicin bladder preservation perfusion chemotherapy, without serious adverse reactions. Its clinical application is safe. And it is important to prevent re- currence after TURBt.
出处 《浙江创伤外科》 2013年第6期805-807,825,共4页 Zhejiang Journal of Traumatic Surgery
关键词 膀胱癌 膀胱癌经尿道膀胱肿瘤电切术(TURBt) 吡柔比星 化疗 复发率 Bladder cancer Transurethral resection of bladder tumor (TURBt) Pirarubicin, Chemotherapy Recurrence rate
  • 相关文献

参考文献10

二级参考文献75

共引文献111

同被引文献18

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部